- Report
- April 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- November 2021
- 101 Pages
Global
From €4040EUR$4,500USD£3,441GBP
- Report
- August 2022
- 120 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- April 2023
- 117 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- March 2024
- 200 Pages
Global
From €3726EUR$4,150USD£3,173GBP
- Report
- January 2024
- 156 Pages
United States
€3412EUR$3,800USD£2,905GBP
- Report
- January 2024
- 114 Pages
United States
€3142EUR$3,500USD£2,676GBP
- Report
- July 2018
- 30 Pages
Global
From €8979EUR$10,000USD£7,646GBP
Symbicort is a combination medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients: budesonide, a corticosteroid, and formoterol, a long-acting beta-agonist. Symbicort is used to reduce inflammation and open up the airways in the lungs, allowing for easier breathing. It is available in both an inhaler and a dry powder inhaler.
Symbicort is part of a larger class of respiratory drugs known as bronchodilators. These drugs are used to treat a variety of respiratory conditions, including asthma, COPD, and bronchitis. Other bronchodilators include albuterol, salmeterol, and ipratropium.
Symbicort is manufactured by AstraZeneca, a British-Swedish pharmaceutical company. Other companies that produce similar medications include GlaxoSmithKline, Boehringer Ingelheim, and Merck. Show Less Read more
